4 min read
Trial Tuesday
Trial Tuesday: Beyond The Topline
BMS’s myeloma pill and Merck’s eye drug both hit their endpoints this week and both left questions unanswered, while investors mapped out a US–China future for drug development.
More from this edition
Trial Tuesday: UK Trial Approvals Get Faster as Industry Enrollment Falls for a Fifth Year
The UK has sped up how fast a study starts. The ABPI says the unsolved part is getting every site open and recruiting.
Capsul Desk
4 min read
members
Trial Tuesday: ADCs And Method Marks In Madrid
Aakash Babu
4 min read
members
Trial Tuesday: Eyes Wide Open Ahead Of ESMO 2026
Manas Mishra
4 min read
members
Trial Tuesday: Lilly Steals The Show In Milan
Manas Mishra
4 min read
members
Trial Tuesday: R&D Posts Favor AI Muscles, Plus A (Brief?) Lull In China
Who, and what, gets trusted with the next decade of drug discovery. The answers, so far: an AI résumé, and in China, a shrug.
Manas Mishra
5 min read
members
Trial Tuesday: Wisdom Of The Masses
Daraxonrasib doubles survival in pancreatic cancer, BMS puts numbers behind its CELMoD bet, and the trial count quietly falls again.
Manas Mishra
8 min read
members